No. The multi-panel urine cups, dip cards, and oral fluid tests used in most workplace, clinical, and correctional drug testing programs do not detect xylazine. Xylazine is not an opioid, amphetamine, benzodiazepine, or any other drug class that a standard panel is designed to catch, so it will not trigger a line on a cup even if that same specimen tests positive for fentanyl. Finding xylazine requires a dedicated xylazine test strip or a laboratory toxicology test built specifically to look for it.
That gap matters because xylazine, a veterinary sedative widely known on the street as "tranq," is now turning up mixed into the illicit fentanyl supply across nearly the entire country. This guide explains what xylazine is, why it slips past routine screening, how it is actually detected, and what harm reduction programs, treatment centers, and testing labs should know before they build it into a program.
What Is Xylazine, and Why Is It Showing Up in Drug Tests?
Xylazine is a sedative, analgesic, and muscle relaxant that the FDA has approved for veterinary use only, primarily as a large-animal tranquilizer. It has never been approved for use in humans. According to the U.S. Drug Enforcement Administration's Diversion Control Division, xylazine is "a powerful non-opiate sedative, analgesic, and muscle relaxant" that is commonly encountered mixed with fentanyl in the illicit drug supply. DEA reports that it has seized xylazine-fentanyl mixtures in 48 of 50 states and Washington, D.C.
The federal government has formally recognized the scale of the problem. On April 12, 2023, the White House Office of National Drug Control Policy designated "fentanyl adulterated or associated with xylazine" as an emerging threat to the United States, the first time that designation authority had been used since Congress created it in 2018. The designation cited forensic laboratory identifications of xylazine rising in every U.S. census region between 2020 and 2021, most sharply in the South (up 193 percent) and the West (up 112 percent), alongside xylazine-involved overdose deaths that climbed 1,127 percent in the South, 750 percent in the West, more than 500 percent in the Midwest, and more than 100 percent in the Northeast over the same period.
Xylazine Is Not an Opioid, and That Changes How Overdoses Are Handled
The DEA explicitly classifies xylazine as a non-opiate. That single fact drives most of the public health concern around it. Naloxone, the medication used to reverse an opioid overdose, works by blocking opioid receptors; it has no mechanism for reversing a non-opioid sedative like xylazine. There is currently no approved medication for reversing xylazine's effects in humans.
Responders should still give naloxone during a suspected overdose, because xylazine is almost always found combined with an opioid such as fentanyl or heroin, and naloxone can still reverse the opioid component of that mixture. But a person exposed to xylazine may remain sedated, and their breathing may remain dangerously slowed, even after naloxone has been administered. Calling emergency medical services immediately is essential in any suspected overdose involving xylazine.
Why Standard Multi-Panel Tests Miss Xylazine
Multi-panel urine cups, dip cards, and oral fluid devices work by using antibodies calibrated to specific drug classes: opiates, amphetamines, THC, cocaine, PCP, benzodiazepines, and on more advanced panels, fentanyl. Because xylazine is chemically unrelated to all of those classes, it does not bind to any of the antibody lines built into a standard immunoassay device. This holds true even for comprehensive fentanyl panels. A 14- to 20-panel cup built to flag fentanyl and other emerging opioids, for example, still is not designed to flag xylazine, since the two substances work on entirely different receptor pathways. Employers, treatment programs, and testing labs sometimes assume that a broader panel automatically covers xylazine risk; it does not.
How Xylazine Is Actually Detected
There are two practical ways xylazine gets identified today, and they serve different purposes.
The first is a xylazine-specific lateral-flow test strip, the same rapid-strip format popularized by fentanyl test strips, but built with antibodies targeting xylazine instead. These strips are used primarily in drug-checking and harm reduction settings: a small amount of the drug sample is dissolved in water, the strip is dipped for several seconds, and a result reads out in about five minutes. Independent testing of one widely used xylazine strip found high sensitivity (100 percent) but more variable specificity, with reliable detection above roughly 2.5 micrograms per milliliter of xylazine in the sample and less consistent results below that threshold. It is worth noting that these strips are generally designed to test a drug sample itself before use, which is a different application than testing a biological specimen such as urine.
The second path is laboratory-based toxicology testing, typically liquid chromatography paired with mass spectrometry, run on a urine or blood specimen. This is the method hospitals, medical examiners, forensic labs, and treatment programs use when there is clinical reason to suspect xylazine exposure and a documented, defensible result is needed.
| Test type | What it detects | Typical setting | Turnaround |
|---|---|---|---|
| Standard multi-panel urine cup or oral fluid test (including fentanyl panels) | Opiates, amphetamines, THC, cocaine, benzodiazepines, PCP, and, on extended panels, fentanyl. Not xylazine. | Workplace, DOT, and corrections programs | About 5 minutes on site |
| Xylazine lateral-flow test strip | Xylazine present in a drug sample, checked before use | Harm reduction and drug-checking programs | About 5 minutes |
| Laboratory LC-MS/MS toxicology testing | Xylazine and other emerging adulterants in urine or blood | Hospitals, treatment centers, medical examiners, forensic and reference labs | Days, send-out lab |
Who Should Be Building Xylazine Awareness Into a Testing Program
Xylazine testing is not a fit for every buyer, but it belongs on the radar for several groups specifically:
- Treatment and recovery programs monitoring patients who may be exposed to a fentanyl supply that is increasingly cut with xylazine, where a positive fentanyl result should prompt a conversation about xylazine exposure even though the panel itself will not confirm it.
- Public health and harm reduction organizations distributing drug-checking supplies, where xylazine test strips give people information about what they are about to use.
- Laboratories and clinics that receive specimens from suspected overdose cases or high-risk populations and need a confirmatory pathway beyond a standard immunoassay screen.
American Screening Corp supplies the multi-panel cups, dip cards, and oral fluid devices these programs already rely on for routine screening, including panels built for rehabilitation and addiction treatment center drug testing and broader addiction recovery drug and alcohol testing programs. For confirmation of anything a standard panel cannot answer on its own, including a suspected xylazine exposure, programs typically route the specimen to a reference lab; ASC's laboratory and reference lab drug testing supplies support that intake and collection step. ASC does not currently offer a xylazine-specific test strip or panel, so any program that needs a xylazine determination should pair routine screening with a dedicated strip or a send-out lab test.
Pairing Routine Screening With the Right Follow-Up Testing
The most defensible approach for a program that may encounter xylazine is layered, not a single device. Routine screening, including the kind of comprehensive fentanyl-aware cup covered in ASC's guide to 14- to 20-panel fentanyl multi-drug testing, still does the job it is built for: flagging the drug classes it was designed around, including fentanyl itself. Xylazine sits outside that job description. Where the population served is at meaningful risk of xylazine exposure, harm reduction organizations often add a dedicated xylazine test strip, in the same spirit as the fentanyl test strip programs described in ASC's piece on how fentanyl test strips empower people and save lives. Clinical and forensic settings that need a documented result instead route the specimen to a laboratory for LC-MS/MS confirmation.
Frequently Asked Questions
Does a 14-panel or 20-panel drug test detect xylazine?
No. Panel-based fentanyl and opioid tests, including 14- to 20-panel cups, are not built to flag xylazine because it is chemically unrelated to the drug classes those panels screen for. Detecting it requires a xylazine-specific test strip or a laboratory toxicology test.
Is xylazine an opioid?
No. Xylazine is a non-opioid sedative approved by the FDA for veterinary use only. It works on a different receptor pathway than opioids like fentanyl or heroin.
Does naloxone (Narcan) work on a xylazine overdose?
Naloxone does not reverse xylazine's effects, but responders should still give it during a suspected overdose because xylazine is usually mixed with opioids, and naloxone can reverse the opioid component. Call 911 immediately in any suspected overdose.
Where did the "emerging threat" xylazine designation come from?
The White House Office of National Drug Control Policy designated fentanyl adulterated with xylazine as an emerging threat on April 12, 2023, the first time that federal designation authority has been used since Congress created it in 2018.
How is xylazine actually detected?
Two main ways: a xylazine-specific lateral-flow test strip that checks a drug sample directly, or a laboratory toxicology test using mass spectrometry on a urine or blood specimen.
Do treatment centers need a separate xylazine test?
Programs serving people who may be exposed to the fentanyl supply should consider adding xylazine-specific testing or lab confirmation, since a standard panel will not catch it even if the same specimen tests positive for fentanyl.
This article is for general informational and educational purposes only and does not constitute medical, clinical, or legal advice. Drug test devices, including fentanyl and xylazine test strips, provide a preliminary screening result, not a diagnosis. Any non-negative or unexpected result should be confirmed through appropriate laboratory testing and reviewed by a qualified medical or clinical professional before any decision is made based on it.
